fosinopril has been researched along with valsartan in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V | 1 |
| Huang, J; Xiang, Y | 1 |
| Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM | 1 |
| Guan, S; Wang, B | 1 |
| Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM | 1 |
| Cheng, JL; Gao, RL; Jing, ZC; Wu, YJ; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Lin, S; Peng, W; Tang, R; Veeraragoo, P; Wu, R; Zhou, Q | 1 |
| Cheng, X; Lin, S; Wu, R; Zhou, Q | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for fosinopril and valsartan
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for fosinopril and valsartan
| Article | Year |
|---|---|
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan | 2000 |
Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Calcium-Transporting ATPases; Collagen; Female; Fosinopril; Hypertrophy, Left Ventricular; Male; Myocardium; Norepinephrine; Rats; Rats, Sprague-Dawley; Sodium-Potassium-Exchanging ATPase; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2000 |
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Collagen; Drug Combinations; Fibrosis; Fosinopril; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Remodeling | 2001 |
Effects of fosinopril and valsartan on expressions of ICAM-1 and NO in human umbilical vein endothelial cells.
Topics: Arteriosclerosis; Cells, Cultured; Endothelium, Vascular; Fosinopril; Humans; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Nitric Oxide; Nitric Oxide Synthase; Tetrazoles; Umbilical Veins; Valine; Valsartan | 2003 |
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2004 |
Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Acute Disease; Animals; Antihypertensive Agents; Blood Flow Velocity; Chemoprevention; Endothelium; Fosinopril; H(+)-K(+)-Exchanging ATPase; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Swine; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Role of Fosinopril and Valsartan on Klotho Gene Expression Induced by Angiotensin II in Rat Renal Tubular Epithelial Cells.
Topics: Angiotensin II; Animals; Cell Line; Epithelial Cells; Fosinopril; Gene Expression Regulation; Glucuronidase; Kidney Tubules; Klotho Proteins; Rats; Tetrazoles; Valine; Valsartan | 2010 |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Glucuronidase; Hypertension; Kidney; Klotho Proteins; Male; Matrix Metalloproteinase 9; Plasminogen Activator Inhibitor 1; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |